ACRIN Breast Committee

1. ACRIN Breast Committee October 1, 2010 Constance Lehman, M.D., PhD, FACR Professor and Vice Chair of Radiology University of Washington ACRIN Breast Committee

2. Breast Committee Members Clinical Breast Imaging Radiologists- Constance Lehman, M.D. PhD Hiroyuke Abe, MD Wendie Berg, M.D. PhD Christiane Kuhl, MD Emily Conant, M.D Laurie Fajardo, M.D Ellen Mendelson, M.D Jay Baker, M.D Chris Comstock, M.D Sina Meisamy, MD Janie Lee, MD Other Radiologists with subspecialization in breast applications Mike Jacobs, M.D David Mankoff, M.D Marilyn Roubidoux, M.D.

3. Other Disciplines Nancy Ellerbroek, M.D Radiation Oncology Tom Julian, M.D Surgical Oncology Shahla Masood, M.D Pathology Charlie Shapiro, M.D. Medical Oncology Isabelle Bedrosian, M.D. Surgical Oncology Physicists Ed Hendrick, PhD Nola Hylton, PhD Martin Yaffe, PhD Robert Nishikawa, PhD

4. Statisticians/Epidemiologists Constantine Gatsonis, PhD Ben Herman, MS Zheng Zhang, PhD Others Barbara LeStage, Patient Advocate Nancy Sauers, Patient Advocate Judy Johnson, Patient Advocate Roslynn Marzan, Research Associate Bernadine Dunning Maxine Crooks Darryl L’Heureux Ashley Fails

5. Historical strength of breast committee Assessment of diagnostic accuracy of relatively mature technology Digital mammography for screening average risk populations Ultrasound for screening high risk populations MRI for screening contralateral breast/diagnosing EOD DCE MRI to assess response to therapy Future development Develop and validate new imaging biomarkers to predict and assess response to therapy Advanced MR imaging (MR spectroscopy, MR DWI), Advanced PET applications, optical imaging

6. SPECIFIC AIMS Test new screening strategies based on individualized risk profiles. Assess the use of imaging for the measurement of extent of disease and for monitoring and mid-therapy adaptation of treatment protocols. Reduce the morbidity of breast cancer therapy through non-invasive imaging-guided mechanisms.

7. Aim 1: Targeted surveillance of at-risk populations Protocol Number 4006 – Tomosynthesis: Comparison of Full Field Digital Mammography with Digital Breast Tomosynthesis (T-MIST) Image Acquisition and Projection Combinations in relation to Screening Call-Back Rate PI: Emily Conant, MD

8. Aim 2: Characterization of cancer in order to drive targeted therapy Protocols applying functional imaging methods to determine the anatomic extent of tumor in order to focus therapy ACRIN 6694 ACOSOG collaboration pre op MRI ACRIN DCIS trial—potential collaboration with SWOG

9. Aim 3: Development of imaging-based predictive and prognostic biomarkers of response to targeted treatment. 6657 extension (MR diffusion, spectroscopy) ISPY2 (6693) EISC FLT study (6688)

10. Concepts approved by ACRIN steering committee ACRIN Concept 6693: MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And molecular Analysis) PI: Nola Hylton, PhD ACRIN Concept 6694 – ACOSOG Z1101: Impact of Breast MRI on Selection and Outcome of Breast Cancer Patients Undergoing Breast Conserving Therapy PI: Isabelle Bedrosian, MD, Surgery PI: Chris Comstock, MD, Imaging

11. 3 Active Trials ACRIN 6683 CAD 1 is complete and was presented at 2009 RSNA. CAD 2 is was presented at this meeting and will be presented at the 2010 RSNA. ACRIN 6657 ISPY Extension: Contrast Enhanced Breast MRI and MRS for evaluation of Patients undergoing neoadjuvant treatment for Locally Advanced Breast Cancer. PI: Nola Hylton, PhD Target accrual 140- accrual to date 114 ACRIN 6688 Phase II study of 3’-Deoxy-3’ 18F Flourothymidine (FLT) in Invasive Breast Cancer PI- Lale Kostakoglu, MD David Mankoff, MD PI Target accrual 54- accrual to date 12

12. Papers Published 7/1/09-6/30/10

13. Abstracts Published 2009